IVIg in Dermatology - EADV

More documents

Recommendations

Info

Chronic urticaria • Study design: Case series (III); randomised study (n-9; I) • Patient numbers: 23 patients (four reports) • Dosage of IVIg: 2g/kg bw/cycle (> 1cycle) • Treatment protocol: monotherapy with IVIg • Duration of observation: 3 years • Results • Largest study with 10 patients: 9/10 responded, 3/9 rapid and prolonged remission • Patients with positive autologous serum test -> weaker or negative test after IVIg in 70% • Small percentage of patients with chronic urticaria may benefit significantly from IVIg • Literatur – O`Donnell et al, Br J Dermatol 1998; 138:101 – Kroiss et al, Acta Derm Venereol 2000; 80:225 – Asero R. Allergy 2000, 55: 1099 – 1101 – Dawn G et al. Br J Dermatol 2003, 149: 836 - 840 EADV 2007
Atopic eczema • Study design: Case series (III); randomised study (n-9; I) • Patient numbers: 10 children, 30 adults • Dosage of IVIg: 1 - 2g/kg bw/cycle (1 – 11 cycles) • Treatment protocol: monotherapy with IVIg (23 patients), adjuvant therapy (17 patients) • Duration of observation: 3 – 6 months • Results • 9/10 children improved (monotherapy) • 10/17 adults with adjuvant treatment improved • Non-Responders were treated with low-dose prednisolone. • Adults: 60% for 2-4 months as adjuvant therapy • children: 90% as monotherapy • Literatur – Jolles S, Hughes J. Int Immunopharmacol 2006, 6: 579 – 591 – Jolles S et al. Acta Derm Venereol 2003, 83: 433 - 437 EADV 2007
Page 1: IVIg in Dermatology Update EADV 200
Page 10 and 11: Registered indications for IVIg Sub
Page 12 and 13: Dermatomyositis • Incidence 1:100
Page 14 and 15: Involvement of other organs • Gen
Page 16: Cytokines •TNF alpha •IL-1 •I
Page 25 and 26: Indications for IVIG in autoimmune
Page 27 and 28: Pemphigus • Pemphigus vulgaris ap
Page 29 and 30: Pemphigoid • Bullous Pemphigoid -
Page 31 and 32: Epidermolysis bullosa acquisita •
Page 33: Study design: randomised, prospecti
Page 37 and 38: Pyoderma gangraenosum • Study des
Page 39: IVIG in vasculitis and connective t
Page 46: Der Einsatz von Immunglobulinen bei

IVIg in Dermatology - EADV

Create successful ePaper yourself

Delete template?

Save as template?